Analysis of pegylated interferon alpha-2a efficacy in the treatment of chronic hepatitis C / 中国基层医药

Objective To investigate the clinical efficacy and safety of the pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C.Methods 170 cases of patients with chronic hepatitis C were included in the study,by using digital table method they were randomly divided into two groups,the observation group of 85 cases were treated with PEG-IFN-alpha-2a therapy,and 85 cases in the control group using ordinary interferon alpha-2b therapy.Curative effect and safety of two groups of patients were compared.Results The obser-vation group treated for 12 weeks,24 weeks and 24 weeks of alanine aminotransferase (ALT)and improvement rate were respectively 70.59%,80%,92.94%,which were higher than that of the control group (52.94%,62.35% and 70.58%)(χ2 =5.42,6.71,4.83,all P<0.05).The observation group for 12 weeks,24 weeks and 24 weeks of HCV-RNA negative rate were 64.71%,75.29%and 91.76%,obviously were higher than the control group of50.59%, 61.18% and 70.59% (χ2 =4.28,7.68,6.31,all P<0.05).Adverse reaction rates were not statistically signifi-cant.Conclusion The pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C has a significant curative effect of PEG-IFN-alpha-2a therapy in chronic hepatitis C,which is better than the ordinary interferon alpha-2b,and is worthy of extensive promotion and application.

Papilomatosis esofágica: a propósito de un caso / Esofagic Papilomatosis / in relation to a case

Los tumores benignos del esófago son raros, constituyendo solo el 0,5 al 0,8 por ciento de todos los tumores esofágicos. Aproximadamente el 60 por ciento de los tumores benignos del esófago son leiomiomas, el 20 por ciento son quistes y el 5 por ciento son pólipos. El resto de las lesiones ocurren con una frecuencia menor del 2 por ciento y constituyen curiosidades y dentro de ellas tenemos al papiloma. Los papilomas son tumores benignos fibrosos y sésiles cubiertos por epitelio escamoso producidos por el papilomavirus humano (VPH), que tienen la capacidad de producir lesiones proliferativas en piel y/o mucosas. En el tubo digestivo se localizan más frecuentes hacia los extremos proximales (boca) y dístales (recto). El caso que se presentó se trata de una localización esofágica distal en un paciente de 49 años de edad, masculino, con sintomatología sugestiva de una enfermedad por reflujo gastroesofágico y/o un trastorno de la motilidad esofágica, diagnosticándosele -por endoscopia y biopsia- lesiones elevadas esofágicas y la presencia de coilocitos. Se le indicó tratamiento con interferón alfa 2 recombinante, quedando pendiente de evolución endoscópica e histológica post-tratamiento.

The benign tumors of the esophagus are rare, being only the 0,5-0,8 percent of all the esophageal tumors. Around the 60 percent of the benign esophageal tumors are leiomyomas, 20 percent are cists and 5 percent are polyps. The rest of the lesions occur with a frequency less than 2 percent being curiosities, and among them there is the papilloma. The papilloma are benign, fibrous and sessile tumors covered by a squamous epithelium produced by the human papilloma virus (HPV), having the capacity of producing proliferative lesions in the skin and/or mucosa. In the digestive tract they are more frequently located to the proximal (mouth) and distal (rectum) endings. In the case we present, it is a distal esophageal location in a male patient aged 49, with symptoms suggesting a disease by gastro-esophageal reflux and/or disturbances of the esophageal motility, arriving to the diagnosis by endoscopy and biopsy: elevated esophageal lesions and the presence of koilocytes. We indicated a treatment with Recombinant Alpha 2 Interferon, being pending the post-treatment endoscopic and histological evolution.

Early Response to Combination of Lamivudine and Interferon Alpha-2b in Patients with Posifive e Antigen of Chronic Hepatitis B / 医学研究杂志

Objective To observe the early efficacy and safety of combined sequential administration of lamivudine and interferon alfa-2b in patients with hepatitis Be antigen (HBeAg)-positive chronic hepatitis B. Methods 71 patients were divided into combined therapy growp (23 eases),interferon group (27 cases) and lamivudine group (21 cases).patients in the first group were given sequential combination treatment with of lamivudine monotherapy for nine weeks followed by lamivudine plus interferon alfa-2b for 15 weeks while patients in the interferon group and Lamivudine group received interferon alfa-2b monotherapy and lamivudine respectively. Results At 24weeks, 43.37% of the patients who received sequential combination treatment and 33.33% of those who received interferon alfa-2b monotherapy had HBeAg seroconversion,which is higher than those who received lamivudine monotherapy(9.52%, P0.05). The normolization rates of ALT in combining group , interferon group and Lamivudine group were 60.87%, 51.85% and 19.04% respectively(P

Clinical significance of HBV-DNA quantitation for antiviral therapy in patients with chronic hepatitis B / 中国基层医药

Objective To explore the clinical significancer of HBV-DNA quantitation for antiviral therapy in patients with chronic hepatitis B.Methods 125 patients were divided into two groups:group A 75 patients whose HBV-DNA quantitation were 1.0?10~5～9.9?10~6 copies/ml and group B 50 patients whose HBV-DNA quantita- tion were more than 1.0?10~7 copies/ml.Two groups were treated with interferon for half a year.Results The therapcutic effect for patients with low level HBV-DNA copies(group A)was better than that with high level HBV- DNA copies(group B).Conclusion The rates of HBV-DNA are closely related to the effect of antiveral therapy; The dynamic detection of HBV-DNA quantitation is helpful to the diagnosis,montioring,evaluation and antiviral therapy in patients with chronic hepatitis B.

Pharmacokinetics study of albumin-interferon ?-2b fusion protein (HSA-IFN?-2b) in Rhesus Monkey / 中国药理学通报

Aim To investigate the pharmacokinetics of albumin-interferon ?-2b fusion protein(HSA-IFN?-2b) in Rhesus monkeys.Methods Three groups of monkeys were administrated by single injection of HSA-IFN?-2b at 50 ?g?kg-1 iv,50 ?g?kg-1 sc and 300 ?g?kg-1 sc,respectively.Blood samples were taken at 14 different time points from each animal.ELISA was employed to determine the drug concentrations in plasma for all samples.Results Drug was detectable in all of the treated monkeys up to 336 hours after administration.One-compartment model analysis showed that distribution volume was 71 ml?kg-1 in 50 ?g?kg-1 iv group,67 ml?kg-1 in 50 ?g?kg-1 sc group,and 63 ml?kg-1 in 300 ?g?kg-1sc group,respectively.The absorption of HSA-IFN?-2b was relatively slow when given by subcutaneous injection.After 50 ?g?kg-1 sc,the absorption half-life was 19h and elimination half-life was 53h,the bioavailability(F) was approximately 73%,and the apparent clearance(clearance divided by bioavailability,CL/F) was 0.92 ml?h-1?kg-1.Conclusion The result showed that HSA-IFN?-2b may offer the benefits of less frequent dosing and a potentially improved efficacy profile compared with non-albumin fused IFN-alpha.

Measurement of Serum INF-2? in Patients with SARS and Its Clinical Significance / 中国医师杂志

Objective To observe the level of serum IFN-2? in patients with severe acute respiratory syndrome(SARS). Methods The level of serum IFN-2? in 66 patients with SARS were measured by RIA, and healthy subjects served as control. Results The results showed that level of serum IFN-2? in patients with SARS in active period were significantly higher than that in control, and level of serum IFN-2? in severe type of patients with SARS either rose or fell. Conclusions The change of serum IFN-2? level indicated that cellular immunity participated in immunoreaction to SARS virus. The change of IFN-2? level in severe type of patients with SARS reflected the difference of immunoreaction in the patients.

A Comprison of Cost-effectiveness Between Interferon ?-2b and Lamivudine in Treating Chronic Hepatitis B / 中国药房

0 05),the cost-effectiveness ratios were 762 49 and 111 85 respectively(P

Construction of plant expression vector containing human interferon gene and expression in Ginseng calli / 中国免疫学杂志

Objective:To express human interferon-?2b gene and to explore the feasibility of expressing human gene in plant cells.Methods:The hIFN-?2b coding sequence was amplified by PCR with specific primers and plasmid pBV889 was used as a template,subcloned into middle vector pMD18-T and binary vector pBI121 to obtain plant expression vector pBIFN. The pBIFN was transformed into Agrobacterium tumefaciens strain LBA4404. Then hIFN-?2b gene was introduced into Ginseng callus cells via Agrobacterium-mediated transformation. The positive cells were screened by G418. The transgenic Ginseng calli were confirmed by PCR,RT-PCR,Western blot and WISH/VSV system.Results:Stable integration of the hIFN-?2b gene in the Ginseng callus cells′ genome was confirmed by PCR analysis. RT-PCR analysis showed that there were transcription products. Western blot implied that the given protein was hIFN-?2b. WISH/VSV system assay showed that the expressed hIFN-?2b possessed relatively lower bioactivity.Conclusion:HIFN-?2b has been expressed in transgenic Ginseng calli, which facilitates further investigation of improving the curative effect of orally administered hIFN-?2b.

Effect of Combination Therapy Including Alpha-Interferon in Advanced Renal Cell Carcinoma / 대한비뇨기과학회지

The patient with metastatic renal cell carcinoma at the time of presentation have an average survival of approximately 4 months, and only 10% can be expected to survive 1 year. The treatment of metastatic renal cell carcinoma remains a major public health problem in clinical medicine. Hormonal therapies, including progestational agents, and chemotherapies as single agent or in combinations seldom result in objective tumor regression or prolongation of survival and the response are usually temporary. Immunotherapic approaches to this tumor has not demonstrated a clear impact on growth of the tumor. But alpha-interferon therapy that initiated by deKernion produced 16. 5% response rate. The following results and conclusions are obtained with combination therapy such as a-interferon. nitrosourea, vinblastine and medroxyprogesteron acetate in metastatic renal cell carcinoma. 1. From March 1988 to August 1989, 15 patients with metastatic renal cell carcinoma were studied. Average patient age was 49.3 years. There was 11 men and 4 women. The disease was confined to lung in 46.7% of the patients and a Karnofsky performance status (PS) of 100 was identified in 7%: 13.3 % had PS score <70. 2. Of 15 patients, 4(26.7%) had a complete responses, 1 (6.7%) had a partial response, 3 (20.0%) had a minimal response and 7 (46.7%) had progression with no evidence of response to treatment. Of patients with pulmonary metastases alone, 5 (71.4%) had objective response or stabilization of disease and 2 (28.6%) had progression with no evidence of response to treatment. 1 (100.0%) patient with PS of 100 had partial response and no patients with PS<70 had response to therapy. 3. Median duration of survival in the overall subjects was 47 weeks : nonresponders survived for median of 21 weeks. Median duration of survival in nonresponders with pulmonary metastasis alone was 20 weeks. All responders are alive at least 33 weeks later. 4. The most common side effects were constitutional symptoms (73.3%). Hematologic toxicity (60%), gastrointestinal toxicity (40%), hepatic toxicity (26.7%) and nephrotoxicity (6.7%) occurred. Severe toxicity was noted only in 1 patient. 5. Natural killer cell activity in responders was 35.4 % and in nonresponders was 43.0%. Increased natural killer cell in responders was noted after treatment. T Lymphocyte subletting (T3 : cytotoxic T cell, T4 : helper T cell, T8 : suppressor T cell) performed at peritreatment had no statistic significance.In spite of short-term study, combination therapies includirrg alpha-interferon cause objective more regression and prolongation of survival. Futher trial with these regimens seem warranted in the management of metastatic renal cell carcinoma.

Preparation,Characterization and application of monoclonal antibodies to recombinant human interferon—?2a / 中国免疫学杂志

In this report,five mouse hybridoma cell lines secreting monoclonal antibodies to recombi-nant human interferon—?2a(rHu IFN—?2a)were raised.All the monoclonal antibodies with IgGl subclass react with rHu IFN—?2a detected by indirect ELISA with the titers ranging from 1:320,000 to 1:10,240,000 but have no cross reactivity with rHu IFN?l,? and proteins from recombinant E.coli.Two of monoclonal antibodies,designated 3F1 and 5G10,have the ability to neutralize antiviral activity of rHu IFN—?2a.By a competitive ELISA the five monoclonal anti-bodies can be divided into three categories based on their epitope specificities.A sandwich ELISA established by employing 3F1 and 5G10 monoclonal antibodies could detect rHuIFN-?2a or rHuIFN-?2b as few as 60pg/ml?Moreover,3F1 monoclonal antibody displayed a satisfactoryproperty in affinity chromatography for rHuIFN?2a,which is able to match a monoclonal anti-body NK2 from CellTech Corporation.